Study: MERCURY-3 trial results support efficacy of Roclanda
September 16th 2023MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.
Study: Researchers discover a key failure in AMD that may lead to progression and vision loss
September 15th 2023According to the Louisiana State University Health Sciences Center, elovanoids have been shown to restore the structure and integrity of damaged photoreceptor cells by repairing, remodeling and regenerating healthy cells.
Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)
September 13th 2023Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss dry eye disease and the various approaches clinicians can take to treat the disease in part 4 of the Viewpoints Podcast.
Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)
September 13th 2023Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss dry eye disease and the various approaches clinicians can take to treat the disease in part 3 of the Viewpoints Podcast.
Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 2)
September 13th 2023Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss dry eye disease and the various approaches clinicians can take to treat the disease in the second part of the Viewpoints Podcast.
Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 1)
September 13th 2023In this podcast, Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss dry eye disease and the various approaches clinicians can take to treat the disease.
Ocugen announces positive clinical study update from the phase 1/2 trial of OCU400
September 13th 2023According to the company, the clinical study update suggests continued positive trends in best-corrected visual acuity and multi-luminance mobility testing as well as positive trends in low-luminance visual acuity among treated eyes.
Researchers: Older people may have glaucoma without realizing it
September 12th 2023According researchers at the University of Gothenburg, for patients who recently received a diagnosis, discovery of glaucoma could mean they start treatment with daily eye drops that lower the pressure in the eye and slow down the damage to the optic nerve.
OWL Leadership Summit 2023: Navigating ophthalmic leadership challenges and embracing diversity
September 12th 2023The Ophthalmic World Leaders (OWL) Leadership Summit, scheduled for September 21 and 22, 2023, in Austin, Texas, will feature a lineup of prominent speakers and engaging discussions on a wide range of leadership topics and industry insights.
Actress Debbie Allen stresses importance of eye health as part of Gr8 Eye Movement campaign
September 11th 2023Debbie Allen, an award-winning actress, dancer, choreographer, singer-songwriter, director and producer is teaming up with Prevent Blindness and Regeneron for the Gr8 Eye Movement, an awareness campaign that aims to educate and encourage those who are at risk of certain retinal diseases to prioritize their eye health.
Opus Genetics doses first patient in Phase 1/2 trial of OPGx-LCA5 in patients diagnosed with LCA5
September 11th 2023According to the company, OPGx-LCA5 is designed to address vision loss due to Leber congenital amaurosis associated with mutations in the LCA5 gene, which causes one of the most severe early-onset retinal dystrophies.